CN111247152B - 作为激酶抑制剂的环状亚氨基嘧啶衍生物 - Google Patents

作为激酶抑制剂的环状亚氨基嘧啶衍生物 Download PDF

Info

Publication number
CN111247152B
CN111247152B CN201880067947.0A CN201880067947A CN111247152B CN 111247152 B CN111247152 B CN 111247152B CN 201880067947 A CN201880067947 A CN 201880067947A CN 111247152 B CN111247152 B CN 111247152B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
isotopic derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880067947.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111247152A (zh
Inventor
陈晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bichen Pharmaceutical Technology Co ltd
Original Assignee
Bichen Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bichen Pharmaceutical Technology Co ltd filed Critical Bichen Pharmaceutical Technology Co ltd
Publication of CN111247152A publication Critical patent/CN111247152A/zh
Application granted granted Critical
Publication of CN111247152B publication Critical patent/CN111247152B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880067947.0A 2017-09-20 2018-09-20 作为激酶抑制剂的环状亚氨基嘧啶衍生物 Active CN111247152B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
US62/561,142 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (2)

Publication Number Publication Date
CN111247152A CN111247152A (zh) 2020-06-05
CN111247152B true CN111247152B (zh) 2024-07-16

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880067947.0A Active CN111247152B (zh) 2017-09-20 2018-09-20 作为激酶抑制剂的环状亚氨基嘧啶衍生物

Country Status (9)

Country Link
US (2) US11254680B2 (https=)
EP (1) EP3684772B1 (https=)
JP (1) JP7394768B2 (https=)
KR (1) KR102796209B1 (https=)
CN (1) CN111247152B (https=)
AU (1) AU2018338098B2 (https=)
CA (1) CA3076202A1 (https=)
MX (1) MX2020003126A (https=)
WO (1) WO2019060611A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
CA3179671A1 (en) * 2020-08-07 2022-02-10 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
TW202539670A (zh) * 2024-02-23 2025-10-16 大陸商海思科醫藥集團股份有限公司 Braf抑制劑的製備方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100216779A1 (en) 2007-06-01 2010-08-26 Glaxosmithkline Llc Imidazopyridine Kinase Inhibitors
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
PL2647637T3 (pl) * 2010-12-02 2016-06-30 Medpacto Inc Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
EP2897618B1 (en) 2012-09-24 2021-11-17 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9321762B2 (en) 2013-12-11 2016-04-26 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
MX385110B (es) * 2014-07-16 2025-03-11 Dev Ct Biotechnology Compuestos de quinoxalina, método para preparar los mismos y uso de los mismos.
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物

Also Published As

Publication number Publication date
JP7394768B2 (ja) 2023-12-08
US11932647B2 (en) 2024-03-19
EP3684772B1 (en) 2023-12-06
RU2020113707A (ru) 2021-10-20
JP2020534373A (ja) 2020-11-26
RU2020113707A3 (https=) 2021-12-23
US20220251089A1 (en) 2022-08-11
CN111247152A (zh) 2020-06-05
EP3684772C0 (en) 2023-12-06
KR20200055034A (ko) 2020-05-20
BR112020005455A2 (pt) 2020-09-24
MX2020003126A (es) 2020-10-01
AU2018338098A1 (en) 2020-05-07
CA3076202A1 (en) 2019-03-28
AU2018338098B2 (en) 2024-02-22
EP3684772A1 (en) 2020-07-29
WO2019060611A1 (en) 2019-03-28
KR102796209B1 (ko) 2025-04-16
US20200247813A1 (en) 2020-08-06
US11254680B2 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
CN111247152B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
KR102887500B1 (ko) Egfr 억제제 및 이의 제조방법 및 응용
CN109963854B (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2021203768A1 (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CN107428742A (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
WO2019154294A1 (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
WO2019174607A1 (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN110156783B (zh) 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
JP2023554391A (ja) キナーゼ阻害剤およびそれらの使用
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
WO2022002100A1 (zh) 新型苯并咪唑化合物
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK40031627B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CN110684020B (zh) 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2025026195A1 (zh) 取代的含氮双环化合物及其用途
BR112020005455B1 (pt) Compostos derivados de iminopirimidina cíclica, composição farmacêutica que os compreende, seu uso e método in vitro ou ex vivo para inibir atividade de uma cinase b-raf v600e em uma célula
CN115403568A (zh) 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
WO2025087295A1 (zh) 一种pi3k抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031627

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant